Boone L I, Knauer K W, Rapp S W, Stewart J F, Modiano J F
Department of Veterinary Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station 77843-4461, USA.
J Am Vet Med Assoc. 1998 Oct 1;213(7):999-1001.
A 7-year-old German Shepherd dog was referred for evaluation of severe nonregenerative anemia (PCV, 10%; reticulocyte fraction, 0.2%). Cytologic examination of a bone marrow aspirate indicated erythroid predominance and dyserythropoiesis, and a diagnosis of myelodysplastic syndrome (MDS) with erythroid predominance was made. The dog was given a single blood transfusion and was treated with prednisone and recombinant human erythropoietin (EPO). Eight weeks later, anemia had resolved. The dog remained clinically normal 30 months after treatment, with a PCV of 45%. Results suggest that EPO may be useful in the treatment of dogs with MDS with erythroid predominance or erythroleukemia. Additional studies are required to confirm the benefit of EPO to manage MDS-associated anemia in dogs.
一只7岁的德国牧羊犬因严重非再生性贫血（红细胞压积，10%；网织红细胞比例，0.2%）前来接受评估。骨髓穿刺液的细胞学检查显示红系细胞占优势且存在红细胞生成异常，诊断为以红系细胞为主的骨髓增生异常综合征（MDS）。该犬接受了一次输血，并接受泼尼松和重组人促红细胞生成素（EPO）治疗。8周后，贫血症状消失。治疗30个月后，该犬临床状况正常，红细胞压积为45%。结果表明，EPO可能对治疗以红系细胞为主的MDS或红白血病犬有用。需要进一步研究以证实EPO对治疗犬MDS相关贫血的益处。
